Intratumor Heterogeneity of KRAS Mutation Status in Pancreatic Ductal Adenocarcinoma Is Associated with Smaller Lesions

Pancreas

Volumn 45, Issue 6, 2016, Pages 876-881

  Nagawkar, Sima S ^a   Abu Funni, Samah ^a   Simon, Einav ^b   Bick, Tova ^b   Prinz, Elad ^a   Sabo, Edmond ^a,b   Ben Izhak, Ofer ^a,b   Hershkovitz, Dov ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Institute of Pathology   (Israel)

Author keywords

intratumor heterogeneity; KRAS; pancreatic ductal adenocarcinoma; subclonality

Indexed keywords

K RAS PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21;

AGED; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MALE; MORPHOMETRICS; PANCREAS ADENOCARCINOMA; PATHOLOGY; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; DISEASE COURSE; GENE FREQUENCY; GENETIC HETEROGENEITY; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PANCREAS; PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES; SURVIVAL ANALYSIS;

AGED; ANALYSIS OF VARIANCE; BASE SEQUENCE; CARCINOMA, PANCREATIC DUCTAL; DISEASE PROGRESSION; FEMALE; GENE FREQUENCY; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS;

EID: 84949472002     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/MPA.0000000000000562     Document Type: Article

References (34)

1. Siegel RL Miller KD Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65: 5-29.
2. Almoguera C Shibata D Forrester K Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988; 53: 549-554.
3. Jones S Zhang X Parsons DW Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321: 1801-1806.
4. Waddell N Pajic M Patch AM Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518: 495-501.
5. Yachida S Jones S Bozic I Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010; 467: 1114-1117.
6. Z'graggen K Rivera JA Compton CC Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas. Ann Surg. 1997; 226: 491-498.
7. Shi C Fukushima N Abe T Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther. 2008; 7: 353-360.
8. Collins MA Bednar F Zhang Y Oncogenic KRAS is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012; 122: 639-653.
9. Collins MA Brisset JC Zhang Y Metastatic pancreatic cancer is dependent on oncogenic Kras in mice. PLoS One. 2012; 7: e49707.
10. Ying H Kimmelman AC Lyssiotis CA Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012; 149: 656-670.
11. Hanahan D Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-674.
12. Almendro V Marusyk A Polyak K. Cellular heterogeneity and molecular evolution in cancer. Annu Rev Pathol. 2013; 8: 277-302.
13. Efrati E Elkin H Peerless Y LNA-based PCR clamping enrichment assay for the identification of KRAS mutations. Cancer Biomark. 2010; 8: 89-94.
14. Robinson JT Thorvaldsdóttir H Winckler W Integrative genomics viewer. Nat Biotechnol. 2011; 29: 24-26.
15. Thorvaldsdóttir H Robinson JT Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 2013; 14: 178-192.
16. Kanda M Matthaei H Wu J Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012; 142: 730.e9-733.e9.
17. de Bruin EC Taylor TB Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med. 2013; 5: 101.
18. Burrell RA McGranahan N Bartek J The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501: 338-345.
19. Bedard PL Hansen AR Ratain MJ Tumour heterogeneity in the clinic. Nature. 2013; 501: 355-364.
20. Chang HJ Han SW Oh DY Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab. Jpn J Clin Oncol. 2011; 41: 593-599.
21. Liedtke C Broglio K Moulder S Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol. 2009; 20: 1953-1958.
22. Taniguchi K Okami J Kodama K Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 2008; 99: 929-935.
23. Schwarz RF Ng CK Cooke SL Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015; 12: e1001789.
24. Zhang J Fujimoto J Zhang J Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014; 346: 256-259.
25. Mroz EA Tward AD Hammon RJ Intra-tumor genetic heterogeneity and mortality in head and neck cancer: analysis of data from the Cancer Genome Atlas. PLoS Med. 2015; 12: e1001786.
26. Landau DA Carter SL Stojanov P Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152: 714-726.
27. Swanton C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 2012; 72: 4875-4882.
28. Farber L Efrati E Elkin H Molecular morphometric analysis shows relative intra-tumoural homogeneity for KRAS mutations in colorectal cancer. Virchows Arch. 2011; 459: 487-493.
29. Hershkovitz D Simon E Bick T Adenoma and carcinoma components in colonic tumors show discordance for KRAS mutation. Hum Pathol. 2014; 45: 1866-1871.
30. Chiosea SI Sherer CK Jelic T KRAS mutant allele-specific imbalance in lung adenocarcinoma. Mod Pathol. 2011; 24: 1571-1577.
31. Krasinskas AM Moser AJ Saka B KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas. Mod Pathol. 2013; 26: 1346-1354.
32. Malapelle U Sgariglia R De Stefano A KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. J Clin Pathol. 2015; 68: 265-269.
33. Campbell PJ Yachida S Mudie LJ The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467: 1109-1113.
34. Young G Wang K He J Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013; 121: 688-694.